Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | HK1 | P19367 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | PARG | Q86W56 | 6/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31121547 | 1.00 | PKM (0.47) | PKMSMN1; SMN2KMT2AMAPK1MEN1 | |
| SCHEMBL2265043 | 1.00 | PKM (0.47) | PKMSMN1; SMN2KMT2AMAPK1MEN1 | |
| SCHEMBL2264974 | 0.95 | PKM (0.48) | PKMSMN1; SMN2KMT2AMAPK1MEN1 | |
| SCHEMBL30007977 | 0.94 | KMT2A (0.56) | PKMSMN1; SMN2KMT2AMAPK1MEN1 | |
| SCHEMBL919135 | 0.94 | KMT2A (0.56) | PKMSMN1; SMN2KMT2AMAPK1MEN1 | |
| SCHEMBL21104695 | 0.92 | SMN1; SMN2 (0.54) | PKMSMN1; SMN2KMT2AMAPK1MEN1 | |
| SCHEMBL10070529 | 0.90 | PARG (0.44) | PKMSMN1; SMN2KMT2AMAPK1MEN1 | |
| SCHEMBL25171455 | 0.89 | TDP2 (0.56) | PKMSMN1; SMN2KMT2AMAPK1MEN1 | |
| Dioxane SCHEMBL28440846 | 0.84 | PARG (0.49) | PKMSMN1; SMN2KMT2AMAPK1MEN1 | |
| SCHEMBL11856834 | 0.81 | SMN1; SMN2 (0.46) | PKMSMN1; SMN2KMT2AMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108314663-B | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | 多格伍德药品公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-108314663-A | The derivative and application thereof of fluorenes, anthracene, xanthene, Dibenzosuberone and acridine | 多格伍德药品公司 | 2018-07-24 | — | — | CN | disclosed |
| US-9446021-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446021-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9446021-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| EP-2152258-B1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | DOGWOOD PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | DOGWOOD PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | DOGWOOD PHARMACEUTICALS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9120754-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | DOGWOOD PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | ALLERGAN SALES, LLC | 2010-06-03 | — | — | US | disclosed |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | ALLERGAN SALES, LLC | 2010-06-03 | — | — | US | disclosed |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | ALLERGAN SALES, LLC | 2010-06-03 | — | — | US | disclosed |
| WO-2010059142-A1 | ANTHRAQUINONE DIOXIMES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059142-A1 | ANTHRAQUINONE DIOXIMES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-2152258-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | Avalon Pharmaceuticals (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008140792-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140792-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20040019042-A1 | FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | ABBVIE INC. | 2004-01-29 | — | — | US | disclosed |
| US-3983248-A | VIRICIDES | RICHARDSON-MERRELL INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313873-A1 | Derivatives of Fluorene, Anthracene, Xanthene, Dibenzosuberone and Acridine and Uses Thereof | WNT1, CTNND1, CTNNB1 | PKM 4502/4885SMN1; SMN2 4091/4885KMT2A 4484/4885 |
| US-20040019042-A1 | FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS | P2RX3, P2RX1, P2RX2 | PKM 2501/4885SMN1; SMN2 1636/4885KMT2A 3944/4885 |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | WNT1, CTNND1, CTNNB1 | PKM 4502/4885SMN1; SMN2 4091/4885KMT2A 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.